Purines (including Hydrogenated) (e.g., Adenine, Guanine, Etc.) Patents (Class 514/45)
  • Patent number: 11505815
    Abstract: The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising said amine masked moieties.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: November 22, 2022
    Assignee: Nuclera Nucleics, Ltd.
    Inventors: Michael C. Chen, Gordon R. McInroy
  • Patent number: 11453695
    Abstract: The compounds are nucleoside and nucleotide analogues that can be used as anticancer or antiviral agents.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 27, 2022
    Assignee: LCB Pharma Inc.
    Inventors: Yvan Guindon, Philippe Mochirian, Mona Nemer, Michel Prévost
  • Patent number: 11434255
    Abstract: The compounds are nucleoside and nucleotide analogues that can be used as cardioprotective agents. The compounds include tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary stereogenic all-carbon centers at the 2? position and a phosphonate ester at C5? position.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 6, 2022
    Assignee: LCB Pharma Inc.
    Inventors: Yvan Guindon, Philippe Mochirian, Mona Nemer
  • Patent number: 11400139
    Abstract: Embodiments of the technology described herein are based, in part, upon the discovery that NETosis, the formation of neutrophil extracellular traps (NETs) is increased in wounds, in organ fibrosis and in subjects with diabetes. Accordingly, methods for treating wounds, fibrosis and NET associated complications in diabetes are provided. The methods comprise administrating a therapeutically effective amount of at least one anti-NET compound to a subject in need of treatment, e.g. a PAD 4 inhibitor, a DNase, a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; an inhibitor of NET release, a protease inhibitor, or an elastase inhibitor.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: August 2, 2022
    Assignee: The Children's Medical Center Corporation
    Inventors: Denisa D. Wagner, Siu Ling Wong, Kimberly Lindsay Martinod, Luise Erpenbeck, Jörn Thilo Witsch, Alexander Savchenko
  • Patent number: 11337992
    Abstract: The present invention relates to a liquid composition for use in the treatment of gastroesophageal reflux. The composition of the present invention comprises a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. The composition of the present invention also relates to a medical device comprising a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. Said composition or composition for a medical device being for use in the preventive and/or curative treatment of the symptoms associated with gastroesophageal reflux and the disease caused thereby, as well as for use in the preventive and/or curative treatment of gastroesophageal reflux disorders.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 24, 2022
    Assignee: SOFAR SWISS SA
    Inventors: Andrea Biffi, Sara Sala
  • Patent number: 11298432
    Abstract: The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope 18F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope 18F which can be obtained by or during a method according to the invention and its various uses.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: April 12, 2022
    Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Louisa Barre, Patrice Marchand
  • Patent number: 11291681
    Abstract: Provided is an A3AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Further provided is the use of A3AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits including pharmaceutical compositions including the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. Further provided is the use of an A3AR agonist, such as 2-Chloro-N6-(3-iodobenzyl)-adenosine-5?-N-methyluronamide (CI-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: April 5, 2022
    Assignee: CAN-FITE BIOPHARMA LTD.
    Inventors: Pnina Fishman, Shira Cohen
  • Patent number: 11236334
    Abstract: The present invention addresses the problem of providing a technique for more conveniently delivering a polynucleotide in a less cytotoxic form into a cell. This problem is solved by a polynucleotide modified by a molecule that contains a structure that contains a disulfide bond and/or a thiol group.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: February 1, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Hiroshi Abe, Zhaoma Shu
  • Patent number: 11220552
    Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 11, 2022
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Patent number: 11207326
    Abstract: The present invention provides a solution mixture of 1.8 to 3.7% hypertonic saline, 70 to 85% ethanol as solvent alternating with 10 milliliters 50 to 90% of 75 to 110 mg theobromine in a nebulized aerosol for inhalation by COVID-19 and SARS patients. Alternatively, theobromine may be infused alternating with inhaled nebulized exogenous pulmonary surfactant as replacement. For advanced COVID-19, SARS patients, the inhalation described above may be alternated with an intravenous solution of 1.8% to 2.2% hypertonic solution of theobromine as 450 mg to 650 mg in ethanol, twice daily.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: December 28, 2021
    Inventors: Binyomin A. Cohen, Monicka C. Jones
  • Patent number: 11141427
    Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: October 12, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventor: William Mark Erwin
  • Patent number: 11135181
    Abstract: Provided herein are methods and compositions for use in the treatment of depression, anxiety or a depressive or anxiety-related disorder. Embodiments describe the administration of orotic acid or a salt thereof, or the administration of one or more probiotic microorganisms, or administration of a combination of orotic acid or a salt thereof and one or more probiotic microorganisms.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: October 5, 2021
    Assignee: Medlab IP Pty Ltd
    Inventors: Luis Vitetta, Samantha Maree Coulson, Sean Hall
  • Patent number: 11110111
    Abstract: The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 7, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Michio Hirano, Caterina Garone, Ramon Marti
  • Patent number: 11059824
    Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: July 13, 2021
    Assignee: Primmune Therapeutics, Inc.
    Inventors: Stephen E. Webber, James Richard Appleman
  • Patent number: 11004539
    Abstract: Provided are drug-transport metabolomics profile assessments and therapies.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: May 11, 2021
    Assignee: The Regents of the University of California
    Inventors: Sanjay K. Nigam, Henry C. Liu
  • Patent number: 10975056
    Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 13, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.
    Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
  • Patent number: 10882861
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 5, 2021
    Assignee: The Research Foundation for the State University of New York
    Inventor: Mark Lukin
  • Patent number: 10815262
    Abstract: The invention relates to methods of preparing nicotinamide riboside and derivatives thereof.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: October 27, 2020
    Assignee: THE QUEEN'S UNIVERSITY OF BELFAST
    Inventors: Marie Migaud, Philip Redpath, Kerri Crossey, Mark Doherty
  • Patent number: 10793855
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: October 6, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • Patent number: 10772854
    Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 15, 2020
    Assignee: First Wave Bio, Inc.
    Inventors: Gary D. Glick, Luigi Franchi, Giancarlo Santus
  • Patent number: 10682372
    Abstract: A problem to be solved by the present invention is to provide a substance having an effect of increasing intracellular ATP and, particularly, a potent ATP enhancer far surpassing the increasing effect of inosine or febuxostat alone. A human or animal intracellular ATP enhancer comprising a combination of A) and B): A) a xanthine oxidase/xanthine dehydrogenase inhibitor or a pharmaceutically acceptable salt thereof; and B) any one or more compounds selected from inosine, inosinic acid, hypoxanthine, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 16, 2020
    Assignee: STAGEN CO., LTD.
    Inventors: Takeshi Nishino, Naoyuki Kamatani
  • Patent number: 10632148
    Abstract: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and so forth. Gallium compounds can be formulated as toothpaste, mouthwash, cream, ointment, gel, solution, eye drops, suppository, and the like. Furthermore, the invention provides methods for controlling microbial growth on environmental surfaces, including those of toothbrush, denture, dental retainer, contact lens, catheter, food stuff, and so forth. In addition, the present invention provides animal feeds which contain gallium compounds that promote the animal growth and prevent the animals from infections as well as protect consumers from post processing infections.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: April 28, 2020
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Daniel P Perl, Sharon Moalem
  • Patent number: 10604542
    Abstract: This disclosure features dinucleotide compounds that modulate Stimulator of Interferon Genes (STING) activity, for use for example in the treatment of cancer. This disclosure also features compositions as well as other methods of using and making the same (Formula (A)). A and B are each independently selected from the group consisting of Formulae (i), (ii), (iii), and (iv).
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: March 31, 2020
    Assignee: Innate Tumor Immunity, Inc.
    Inventors: Gary Glick, Shomir Ghosh, Edward James Olhava, William R. Roush, Roger Jones
  • Patent number: 10579911
    Abstract: Various embodiments can include artificial learning counter surveillance (ALCS) or self-protection surveillance systems (SPSS) and related methods. Apparatuses and methods can include non-destructive electro-optic interference or protection systems as well non-destructive directed energy systems, a control system, and an analysis system for determining an optical system of interest and generating degradation or disruption effects using various equipment items and machine learning systems. Additionally, methods are also provided for determining degree of severity of degradation or disruption based on threshold definitions related to ability to use the optical system of interest for one or more specified applications.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 3, 2020
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventors: Tyler Fitzsimmons, Betsy Marschand, Clay Armstrong, Joshua Borneman, Aaron Cole, Lauren Christopher
  • Patent number: 10457627
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: October 29, 2019
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10428104
    Abstract: Compounds such as: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds to treat neoplasms have been disclosed.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 1, 2019
    Assignee: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue
  • Patent number: 10398692
    Abstract: An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of citric acid. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: September 3, 2019
    Assignee: Curatek Pharmaceuticals Holding, Inc.
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 10292951
    Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: May 21, 2019
    Assignee: First Wave Bio, Inc.
    Inventors: Gary D. Glick, Luigi Franchi, Giancarlo Santus
  • Patent number: 9969802
    Abstract: Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: May 15, 2018
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki Ebinuma, Kohei Takubo, Isamu Fukamachi, Saishu Yoshida, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
  • Patent number: 9968628
    Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: May 15, 2018
    Assignees: Idenix Pharmaceuticals LLC, Universita Degli Studi Di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paolo LaColla
  • Patent number: 9861811
    Abstract: Apparatus and methods for treating back pain are provided in which electrical stimulation therapy is designed to cause muscle contraction to rehabilitate the muscle, restore neural drive and restore spinal stability. In accordance with one aspect, electrical stimulation is applied through at least one electrode to stimulate efferent motor nerve fibers to cause muscle contraction to facilitate rehabilitation without targeting stimulation of afferent nerve fibers. In accordance with another aspect, a stimulator further includes one or more of a number of additional therapeutic modalities, including a module that provides analgesic stimulation; a module that monitors muscle performance and adjusts the muscle stimulation regime; and/or a module that provides longer term pain relief by selectively and repeatedly ablating nerve fibers.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: January 9, 2018
    Assignee: Mainstay Medical Limited
    Inventors: Peter Andrew Crosby, Dan Sachs, Prashant Brijmohansingh Rawat, Jason Alan Shiroff, Johannes Petrus Heemels
  • Patent number: 9737512
    Abstract: Certain embodiments are directed to methods of treating pain, e.g., chronic or neuropathic pain, comprising administering an effective amount of an EPAC inhibitor.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: August 22, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Xiaodong Cheng, Fang Mei, Annemieke Kavelaars, Cobi J. Heijnen
  • Patent number: 9730944
    Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: August 15, 2017
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Steven De Jonghe, Ling-Jie Gao, Piet Herdewijn, Jean Herman, Miyeon Jang, Pieter Leyssen, Thierry Louat, Johan Neyts, Christophe Pannecouque, Bart Vanderhoydonck
  • Patent number: 9732111
    Abstract: The present invention relates to 2?-Alkynyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one 2?-Alkynyl Substituted Nucleoside Derivative, and methods of using the 2?-Alkynyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: August 15, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Yuhua Huang, Lingyan Wang, Stephane L. Bogen, Angela D. Kerekes, Vinay M. Girijavallabhan, Gabor Butora, Quang Truong, Ian Davies, Ann E. Weber
  • Patent number: 9713622
    Abstract: The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NRTI) selected from lamivudine and emtricitabine; a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) selected from didanosine, abacavir and tenofovir; and the combination of a boosted or unboosted protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir; or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine; or an integrase inhibitor; for daily administration to said human being one to four days per week.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: July 25, 2017
    Assignee: UNIVERSITÉ VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventor: Jacques Leibowitch
  • Patent number: 9631240
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 25, 2017
    Assignee: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • Patent number: 9632090
    Abstract: The subject matter relates to newly discovered nucleic acid molecules and proteins associated with thymic lymphoma and hamartomatous tumors. Compositions and methods for detecting, characterizing, preventing, and treating human thymic lymphoma and hamartomatous tumors are provided.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: April 25, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Ronald A. DePinho, Ji-Hye Paik, Ramya Kollipara
  • Patent number: 9586986
    Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: March 7, 2017
    Assignees: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I., PALACKY UNIVERSITY IN OLOMOUC
    Inventors: Michal Hocek, Petr Naus, Olga Caletkova, Marian Hajduch, Petr Dzubak
  • Patent number: 9579337
    Abstract: The present invention relates to a pharmaceutical or dietary composition comprising deoxyuridine and a pharmaceutically or dietetically suitable carrier. Another aspect of the present invention relates to a method of supplementing the dietary needs of a subject. This method includes administering to the subject a dietary supplementing effective amount of deoxyuridine. Yet another aspect of the present invention relates to a method of treating cancer in a subject. This method includes selecting a subject having cancer and administering to the selected subject a therapeutically effective amount of uridine, thereby treating the cancer in the selected subject.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: February 28, 2017
    Assignee: Cornell University
    Inventors: Patrick J. Stover, Martha S. Field
  • Patent number: 9567627
    Abstract: The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: February 14, 2017
    Assignees: UNIVERSITE DE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventor: Gilles Pages
  • Patent number: 9505796
    Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: November 29, 2016
    Assignee: Crozet Medical GmbH
    Inventors: Jurgen Schrader, Christa Muller, Ali El-Tayeb, Jamshed Iqbal
  • Patent number: 9464326
    Abstract: Toll-like receptors (TLR) are expressed by a variety of cancers, including melanoma and T-ALL. TLR signaling plays an important role in T cell malignancies and melanoma. The effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4 in melanoma and T-ALL cells were evaluated. Pharmacological treatment with an IRAK-1,-4 inhibitor delays tumor growth and prolongs survival in vitro and in vivo, indicating that TLR signaling contributes to T-ALL and melanoma progression and interfering with this signaling is a novel therapeutic strategy to control T-ALL and melanoma proliferation.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 11, 2016
    Assignee: University of Maryland, Baltimore
    Inventor: Eduardo Davila
  • Patent number: 9456629
    Abstract: An infant and/or toddler nutrition comprising non-viable Bifidobacterium breve and a non-digestible oligosaccharide and its use are disclosed.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: October 4, 2016
    Assignee: N.V. NUTRICIA
    Inventors: Sander Hougee, Adrianus Johannes Maria Vriesema, Johan Garssen, Jan Knol
  • Patent number: 9452217
    Abstract: Compositions and methods including at least one PNP inhibitor or at least one PNP inhibitor in combination with one or more agents identified as endogenous adjuvants useful in the treatment of pathogen infection and cancer are disclosed. The compositions may be formulated as pharmaceutical dosage forms and components may be assembled as kits. Methods for increasing levels of endogenous adjuvants to enhance an immune response and to potentiate/augment antiviral, antibacterial or anticancer effects of therapeutic agents are also disclosed.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: September 27, 2016
    Assignee: Nitor Therapeutics
    Inventor: Shanta Bantia
  • Patent number: 9422321
    Abstract: The present invention relates to the field of pharmacochemistry. Disclosed are fluorinated and azido-substituted pyrimidine nucleoside derivatives, particularly compounds of the formula shown below: Also disclosed are methods of preparation and uses for these compounds. The compounds can be used for preparing medicaments for treating diseases such as tumors and viral infections, and can be used separately or in combination with other medicaments. The compounds also have effective activity against diseases such as tumors and viral infections, while having few side effects, and thus have potential application value.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: August 23, 2016
    Assignees: High & New Technology Research Center, Henan Academy of Sciences, Zhengzhou Granlen Pharmatech Ltd., Zhengzhou University
    Inventors: Junbiao Chang, Haoyun An, Xuejun Yu, Xiaohe Guo
  • Patent number: 9423405
    Abstract: Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: August 23, 2016
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
  • Patent number: 9387220
    Abstract: The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A3AR agonist. A preferred A3AR agonist disclosed herein is Cl-IB-MECA.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: July 12, 2016
    Assignee: CAN-FITE BIOPHARMA LTD.
    Inventors: Pnina Fishman, Shira Cohen
  • Patent number: 9315535
    Abstract: The present invention provides compounds shown by the formula: wherein Y1 is CR6 or N, Y2 is CR7 or N, Y3 is CR8 or N, R6, R7 and R8 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, Bx is a nucleic acid base moiety, Z1 and Z2 are each independently, a hydrogen atom, a hydroxyl protecting group or a reactive phosphorus group, R1 to R5 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, and n is an integer of 0 to 3, or salts thereof, that are novel nucleosides or nucleotides that can be useful as materials for synthesizing nucleic acid pharmaceuticals.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: April 19, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yasunori Mitsuoka, Akira Kugimiya, Aiko Yamashita
  • Patent number: 9315545
    Abstract: Compounds and methods are described herein that can be used to treat subjects for conditions related to hepcidin activity, such as but not limited diseases of iron metabolism, beta thalassemia, hemochromatosis, iron-loading anemias, alcoholic liver disease, or chronic hepatitis C.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 19, 2016
    Assignee: MERGANSER BIOTECH, INC.
    Inventor: Gene Scott Merutka
  • Patent number: 9301960
    Abstract: The invention provides compositions for inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, comprising an effective amount of a redox-sensitive purine compound and an effective amount of a redox agent. The invention further provides methods of inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, by administering compositions of the invention. Methods of screening for compounds that inhibit a redox-sensitive GTPase protein, including compounds that target and inhibit Rho or Rab family GTPases, are further provided.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 5, 2016
    Assignee: Board of Regents, The University of Texas Systems
    Inventor: Jongyun Heo